American Heart Journal
Volume 144, Issue 6 , Pages 957-980 , December 2002

Changing the diagnosis of acute myocardial infarction: Implications for practice and clinical investigations

References 

  1. Alpert JS, Thygesen K, Antman E, et al.  The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J. 2000;21:1502–1513 J Am Coll Cardiol. 2000;36:959–969
  2. Tunstall-Pedoe H. Redefinition of myocardial infarction by a consensus dissenter. J Am Coll Cardiol. 2001;37:1472–1473
  3. Tunstall-Pedoe H, for the WHO, MONICA Project Principal Investigators . The World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol. 1988;41:105–114
  4. Alpert JS, Thygesen K. Redefinition of myocardial infarction by a consensus dissenter: reply. J Am Coll Cardiol. 2001;37:1473–1474
  5. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: 5th ed.  Braunwald E editors. Heart disease. Philadelphia: : WB Saunders; 1997;p. 742–749
  6. Porela P, Helenius H, Pulkki K, et al.  Epidemiological classification of acute myocardial infarction: time for a change?. Eur Heart J. 1999;20:1459–1464
  7. Hamm CW, Goldman BU, Heeschen C, et al.  Emergency room triage of patients with acute chest pain by means of rapid testing of cardiac troponin T or troponin I. N Engl J Med. 1997;337:1648–1653
  8. Heeschen C, Goldmann BU, Moeller RH, et al.  Analytical performance and clinical application of a new rapid bedside assay for the detection of serum cardiac troponin I. Clin Chem. 1998;44:1925–1930
  9. Newby LK, Kaplan AL, Granger BB, et al.  Comparison of cardiac troponin T versus creatine kinase-MB for risk stratification in a chest pain evaluation unit. Am J Cardiol. 2000;85:801–805
  10. The GRACE Investigators . Rationale and design of the GRACE (Global Registry of Acute Coronary Events) project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J. 2001;141:190–199
  11. Goodman S, Johnson J, Sullivan C, et al.  What is an MI? prospective analysis of the diagnostic and prognostic impact of adding troponins to the definition of myocardial infarction [abstract]. J Am Coll Cardiol. 2001;37:358A
  12. Jaffe AS. Elevations in cardiac troponin measurements: false false-positives. Cardiovasc Toxicol. 2001;1:87–92
  13. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Eur Heart J. 1997;18:1231–1248
  14. Fox KA, Cokkinos DV, Deckers J, et al.  The ENACT study: a pan-European survey of Acute Coronary Syndromes. Eur Heart J. 2000;21:1440–1449
  15. Collinson J, Flather MD, Fox KA, et al.  Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J. 2000;21:1450–1457
  16. Danchin N, Vaur L, Genès N, et al.  Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the “real world”: one-year results from a nationwide French survey. Circulation. 1999;99:2639–2644
  17. Fox KA. Management of acute coronary syndromes: the GRACE registry. Presented at: The European Society of Cardiology Scientific Sessions September 3, 2001;
  18. Battler A. Acute coronary syndromes, medical management and interventional therapy in Europe. Presented at: The European Society of Cardiology Scientific Sessions September 3, 2001;
  19. Task Force of the European Society of Cardiology . Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Eur Heart J. 2000;21:1406–1432
  20. Apple FS, Murakami M, Panteghini M, et al.  International survey on the use of cardiac markers. Clin Chem. 2001;47:587–588
  21. Meier MA, Al-Badr WH, Cooper JV, et al.  The new definition of myocardial infarction: what does it mean clinically? [abstract]. J Am Coll Cardiol. 2001;37:310A
  22. The Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) Investigators . Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet. 2000;355:337–345
  23. Kramer J, Newby LK, Simes J, et al.  Opportunities for enhancing the use of evidence-based medicines for acute coronary syndromes: insights from the SYMPHONY studies [abstract]. J Am Coll Cardiol. 2002;39:303A
  24. Ohman EM, Armstrong PW, Christenson RH, et al.  Cardiac troponin T levels for risk stratification in acute myocardial ischemia. New Engl J Med. 1996;335:1333–1341
  25. Bahit MC, Criger DA, Granger CB, et al.  Elevation of CK-MB greater than 2 fold and troponin greater than 3 fold are the best thresholds for identifying MI associated with ECG evolution [abstract]. J Am Coll Cardiol. 2001;37:115A
  26. Ottani F, Galvani M, Nicolini FA, et al.  Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J. 2000;140:917–927
  27. Antman EM, Tanasijevic MJ, Thompson C, et al.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342–1349
  28. Alexander JH, Sparapani RA, Mahaffey KW, et al.  Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. JAMA. 2000;283:347–353
  29. Sobel BE, Bresnehan GF, Shell WE, et al.  Estimation of infarct size in man and its relation to prognosis. Circulation. 1972;46:640–648
  30. Sobel BE, Roberts R, Larson KB. Estimation of infarct size from serum MB creatine phosphokinase activity: applications and limitations. Am J Cardiol. 1976;37:474–485
  31. Thompson PL, Fletcher EE, Katavatis V. Enzymatic indices of myocardial necrosis, influence on short-term and long-term prognosis after myocardial infarction. Circulation. 1979;59:113–119
  32. Newby LK, Christenson RH, Ohman EM, et al.  The value of serial troponin T measurements for early and late risk stratification in patients with acute coronary syndromes. Circulation. 1998;98:1853–1859
  33. Harrington RA, Lincoff AM, Califf RM, et al.  Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol. 1995;25:1693–1699
  34. Califf RM, Abdelmeguid AE, Kuntz RE, et al.  Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241–251
  35. Abdelmeguid AE, Topol EJ, Whitlow PL, et al.  Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94:1528–1536
  36. Kong TQJ, Davidson CJ, Meyers SN, et al.  Prognostic implication of creatine kinase elevation following elective coronary artery interventions. J Am Med Assn. 1997;277:461–466
  37. Tardiff BE, Califf RM, Tcheng JE, et al.  Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol. 1999;33:88–96
  38. Simoons ML, van den Brand M, Lincoff M, et al.  Minimal myocardial damage during coronary intervention is associated with impaired outcomes. Eur Heart J. 1999;20:1112–1119
  39. Ohman EM, Tardiff BE. Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. J Am Med Assn. 1997;277:495–497
  40. Saucedo JF, Mehran R, Dangas G, et al.  Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol. 2000;35:1134–1141
  41. Webb JG, Carere RG, Virmani R, et al.  Retrieval and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol. 1999;34:468–475
  42. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570–580
  43. Grube E, Gerckens U, Yeung AC, et al.  Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation. 2001;104:2436–2441
  44. The Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Investigators . Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87–92
  45. Abizaid AS, Mehran R, Dangas G, et al.  Positive troponin-I predicts early and late mortality after percutaneous coronary intervention [abstract]. J Am Coll Cardiol. 2001;37:23A
  46. Bertinchant JP, Polge A, Ledermann B, et al.  Relation of minor cardiac troponin T elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty of angina pectoris. Am J Cardiol. 1999;84:51–57
  47. Cantor WJ, Newby LK, Christenson RH, et al.  Elevated troponin-I after percutaneous coronary intervention is a powerful prognostic indicator [abstract]. Circulation. 2000;102(Suppl):II-752
  48. Fuchs S, Kornowski R, Mehran R, et al.  Prognostic value of cardiac troponin I levels following catheter-based coronary interventions. Am J Cardiol. 2000;85:1077–1082
  49. Genser N, Mair J, Friedrich G, et al.  Uncomplicated successful percutaneous transluminal coronary angioplasty does not affect cardiac troponin T plasma concentrations. Am J Cardiol. 1996;78:127–128
  50. Gruberg L, Fuchs S, Mehran R, et al.  Troponin I predicts adverse outcome after percutaneous coronary intervention in patients with chronic renal failure [abstract]. J Am Coll Cardiol. 2001;37:76A
  51. Hunt AC, Chow SL, Shiu MF, et al.  Release of creatine kinase-MB and cardiac specific troponin-I following percutaneous transluminal coronary angioplasty. Eur Heart J. 1991;12:690–693
  52. Johansen O, Brekke M, Stormme JH, et al.  Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. Eur Heart J. 1998;19:112–117
  53. Karim MA, Shinn M, Oskarsson H, et al.  Significance of cardiac troponin T release after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1995;76:521–523
  54. La Vecchia L, Bedogni F, Finocchi G, et al.  Troponin T, troponin I and creatine kinase-MB mass after elective coronary stenting. Cor Art Dis. 1996;7:535–540
  55. Ravkilde J, Nissen H, Mickley H, et al.  Cardiac troponin T and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. Am Heart J. 1994;127:13–20
  56. Saadeddin SM, Habbab MA, Sobki SH, et al.  Minor myocardial injury after elective uncomplicated successful percutaneous transluminal coronary angioplasty with or without stenting: detection by cardiac troponins [abstract]. J Am Coll Cardiol. 2001;37:40A
  57. Shyu K, Kuan P, Cheng J, et al.  Cardiac troponin T, creatine kinase and its isoform release after successful percutaneous transluminal coronary angioplasty with or without stenting. Am Heart J. 1998;135:862–867
  58. Sribhen K, Leowattana W, Kiartivich S, et al.  Cardiac troponin T concentration after coronary balloon angioplasty [letter]. Am J Cardiol. 1997;79:1439
  59. Stromme JH, Johansen O, Brekke M, et al.  Markers of myocardial injury in blood following PTCA: a comparison of CKMB, cardio-specific troponin T and troponin I. Scand J Clin Lab Invest. 1998;58:693–699
  60. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators . Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1999;339:436–443
  61. Simoons ML, for the Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IV-ACS) Investigators . Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation. Lancet. 2001;357:1915–1924
  62. The c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Investigators . Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429–1435
  63. The Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II (IMPACT II) Investigators . Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349:1422–1428
  64. The Evaluation of C73E for the Prevention of Ischemic Complications (EPIC) Investigators . Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956–961
  65. The Evaluation in PTCA to Improve Long-Term Outcome with Abciximab Glycoprotein IIb/IIIa Blockade (EPILOG) Investigators . Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–1696
  66. Akkerhuis KM, Alexander JH, Tardiff BE, et al.  Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?. Circulation. 2002;105:554–556
  67. Driscoll A, Hobika J, Etsten B, et al.  Clinically unrecognized myocardial infarction following surgery. N Engl J Med. 1961;264:633–639
  68. Brewer DL, Bilbro RH, Bartel AG. Myocardial infarction as a complication of coronary bypass surgery. Circulation. 1973;47:58–64
  69. Mauney FM, Ebert PA, Sabiston DC. Postoperative myocardial infarction: a study of predisposing factors, diagnosis and mortality in a high-risk group of surgical patients. Ann of Surgery. 1970;172:497–503
  70. Chaitman BR, Alderman EL, Sheffield LT, et al.  Use of survival analysis to determine the clinical significance of new Q wave after coronary bypass surgery. Circulation. 1983;67:302–309
  71. Dixon SH, Limbird LE, Roe CR, et al.  Recognition of postoperative acute myocardial infarction: application of isoenzymes technique. Circulation. 1973;48,49(3 Suppl):137–140
  72. Warren SG, Wagner GS, Bethea CF, et al.  Diagnostic and prognostic significance of electrocardiographic and CPK isoenzyme changes following coronary bypass surgery: correlation with findings at one year. Am Heart J. 1977;93:189–196
  73. Kennedy JW, Kaiser GC, Fisher LD, et al.  Clinical and angiographic predictors of operative mortality from the collaborative study in coronary artery surgery (CASS). Circulation. 1981;63:793–802
  74. Schaff HV, Gersh BJ, Fisher LD, et al.  Detrimental effect of perioperative myocardial infarction on late survival after coronary artery bypass: report from the coronary artery surgery study-CASS. J Thor Cardiovasc Surg. 1984;88:972–981
  75. Bonnefoy E, Filley S, Kirkorian G, et al.  Troponin I, troponin T, or creatine kinase-MB to detect perioperative myocardial damage after coronary artery bypass surgery. Chest. 1998;114:482–486
  76. Gensini GF, Fusi C, Conti AA, et al.  Cardiac troponin I and Q-wave perioperative myocardial infarction after coronary bypass surgery. Crit Care Med. 1998;26:1986–1990
  77. Horvath KA, Parker MA, Frederiksen JW, et al.  Postoperative troponin I values: insult or injury?. Clin Cardiol. 2000;23:731–733
  78. Jacquet L, Noirhomme P, El Khoury G, et al.  Cardiac troponin I as an early marker of myocardial damage after coronary bypass surgery. Eur J Card Surg. 1998;13:378–384
  79. Greenson N, Macoviak J, Krishnaswamy P, et al.  Usefulness of cardiac troponin I in patients undergoing open heart surgery. Am Heart J. 2001;141:447–455
  80. Mahaffey KW, Alpert JS. Cardiac enzyme elevations after cardiac surgery: the cardiologist's perspective. Am Heart J. 2001;141:321–324
  81. Force T, Hibberd P, Weeks G, et al.  Perioperative myocardial infarction after coronary artery bypass surgery: clinical significance and approach to risk stratification. Circulation. 1990;82:903–912
  82. Klatte K, Chaitman BR, Theroux P, et al.  Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial. J Am College Cardiol. 2001;38:1070–1077
  83. Mahaffey KW, Roe MT, Sparapani R, et al.  Cardiac enzyme elevations after coronary artery bypass grafting associated with increased risk of death: results from PARAGON B [abstract]. J Am Coll Cardiol. 2001;37:359A
  84. Etievent JP, Chocron S, Toubin G, et al.  Use of cardiac troponin I as a marker of perioperative myocardial ischemia. Ann Thorac Surg. 1995;59:1192–1194
  85. Alyanakian MA, Dehoux M, Chastel D, et al.  Cardiac troponin I in diagnosis of perioperative myocardial infarction after cardiac surgery. J Card Vasc Anesth. 1998;12:288–294
  86. Vermes E, Mesguich M, Houel R, et al.  Cardiac troponin I release after open heart surgery: a marker of myocardial protection?. Ann Thorac Surg. 2000;70:2087–2090
  87. Swaanenburg JCJM, Loef B, Volmer M, et al.  Creatine kinase MB, troponin I, and troponin T release pattern after coronary artery bypass grafting with or without cardiopulmonary bypass and after aortic and mitral valve surgery. Clin Chem. 2001;47:584–587
  88. Kilger E, Pichler B, Weis F, et al.  Markers of myocardial ischemia after minimally invasive and conventional coronary operation. Ann Thorac Surg. 2000;70:2023–2028
  89. Braun SL, Barankay A, Mazzitelli D. Plasma troponin T and troponin I after minimally invasive coronary bypass surgery. Clin Chem. 2000;46:279–281
  90. Koh TW, Carr-White GS, DeSouza AC, et al.  Intraoperative cardiac troponin T release and lactate metabolism during coronary artery surgery: comparison of beating heart with conventional coronary artery surgery with cardiopulmonary bypass. Heart. 1999;81:495–500
  91. Krejca M, Skiba J, Szmagala P, et al.  Cardiac troponin T release during coronary surgery using intermittent cross-clamp with fibrillation, on-pump and off-pump beating heart. Eur J Card Surg. 1999;16:337–341
  92. Birdi I, Caputo M, Hutter JA, et al.  Troponin I release during minimally invasive coronary artery surgery. Thorac Cardiovasc Surg. 1997;114:509–510
  93. Carrier M, Pellerin M, Perrault L, et al.  Troponin levels in patients with myocardial infarction after coronary artery bypass grafting. Ann Thorac Surg. 2000;69:435–440
  94. Sadony V, Körber M, Albes G, et al.  Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery. Eur J Card Surg. 1998;13:57–65
  95. Barron JT. Cardiac troponin I and non-Q-wave myocardial infarction: how useful is it after coronary artery bypass surgery?. Crit Care Med. 1998;26:1936–1937
  96. Koh TW, Hooper J, Kemp M, et al.  Intraoperative release of troponin T in coronary venous and arterial blood and its relation to recovery of left ventricular function and oxidative metabolism following coronary artery surgery. Heart. 1998;80:341–348
  97. Eigel P, van Ingen G, Wasgenpfeil S. Predictive valve of perioperative cardiac troponin I for adverse outcome in coronary artery bypass surgery. Eur J Card Surg. 2001;20:544–549
  98. Januzzi JL, Lewandrowski K, MacGillivray TE, et al.  A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. J Am Coll Cardiol. 2002;39:1518–1523
  99. Wagner D, Alspector B, Feingers J, et al.  Clin Chem. 1979;25:1337–1339
  100. Dixon SH, Limbird LE, Roe CR, et al.  Recognition of postoperative acute myocardial infarction: application of isoenzyme techniques. Circulation. 1973;47,48(3 Suppl):III-137–III-140
  101. Righetti A, Crawford MH, O'Rourke RA, et al.  Detection of perioperative myocardial damage after coronary artery bypass graft surgery. Circulation. 1977;55:173–178
  102. Isom OW, Spencer FC, Feigenbaum H, et al.  Prebypass myocardial damage in patients undergoing coronary revascularization; and unrecognized vulnerable period [abstract]. Circulation. 1975;51,52(2 Suppl):II-119
  103. Tomai F, De Paulis R, Penta de Peppo A, et al.  Beneficial impact of isoflurane during coronary bypass surgery on troponin I release. Giornale Italiano di Cardiologia. 1999;29:1007–1014
  104. Mentzer RM, Birjiniuk V, Khuri S, et al.  Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg. 1999;229:643–649
  105. Fitch JC, Rollins S, Matis L, et al.  Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999;100:2499–2506
  106. Wendel HP, Heller W, Michel J, et al.  Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg. 1995;109:1164–1172
  107. Tünerir B, Colak O, Alatas O, et al.  Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg. 1999;68:2173–2176
  108. Hendrikx M, Jiang H, Gutermann H, et al.  Release of cardiac troponin I in antegrade crystalloid versus cold blood cardioplegia. J Thorac Cardiovasc Surg. 1999;118:452–459
  109. Heeschen C, Hamm CW, Goldmann B, et al.  Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999;354:1757–1762
  110. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol. 1997;29:43–48
  111. Newby LK, Ohman EM, Christenson RH, et al.  Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON B troponin T substudy. Circulation. 2001;103:2891–2896
  112. Cannon CP, Weintraub WS, Demopoulos LA, et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887
  113. Hudson MP, O'Connor CM, Gattis WA, et al.  Ongoing myocardial necrosis among outpatients with heart failure: implications of elevated troponin T and C-reactive protein [abstract]. Eur Heart J. 2000;21(Suppl):292
  114. Sato Y, Yamada T, Taniguchi R, et al.  Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 2001;103:369–374
  115. Roppolo LP, Fitzgerald R, Dillow J, et al.  A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing dialysis at a Veteran's Hospital: a pilot study. J Am Coll Cardiol. 1999;34:448–454
  116. Porter GA, Norton T, Bennett WB. Troponin T (TnT), a predictor of death in chronic haemodialysis patients. Eur Heart J. 1998;19(N Suppl):N34–N37
  117. Apple FS, Sharkey SW, Hoeft P, et al.  Prognostic value of serum cardiac troponin I and T in chronic dialysis patients: a 1-year outcomes analysis. Am J Kidney Dis. 1997;29:399–403
  118. Dierkes J, Domrose U, Westphal S, et al.  Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation. 2000;102:1964–1969
  119. Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. Nephrol Dial Transplant. 1998;13:1709–1712
  120. Ooi DS, Zimmerman D, Graham J, et al.  Cardiac troponin T predicts long-term outcomes in hemodialysis patients. Clin Chem. 2001;47:412–417
  121. Braunwald E, Atman EM, Beasley JW, et al.  ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2000;36:970–1062
  122. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators . A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498–1505
  123. The Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease (FRISC II) Investigators . Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708–715
  124. The Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease (FRISC II) Investigators . Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:701–707
  125. Lindahl B, Diderholm E, Lagerqvist B, et al.  Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol. 2001;38:979–986
  126. Antman EM. Troponin measurements in ischemic heart disease: more that just a black and white picture. J Am Coll Cardiol. 2001;38:987–990
  127. Mahaffey KW, Harrington RA, Akkerhuis M, et al.  Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Controlled Trials Cardiovasc Med. 2001;2:180–186
  128. Alexander JH, Sparapani RA, Mahaffey KW, et al.  Eptifibatide reduces the size and incidence of myocardial infarction in patients with non-ST-elevation acute coronary syndromes [abstract]. J Am Coll Cardiol. 1999;33:331A
  129. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators . A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. New Engl J Med. 1997;336:1621–1628
  130. Cohen M, Demers C, Gurfinkel EP, et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. New Engl J Med. 1997;337:447–452
  131. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators . Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl J Med. 1998;338:1488–1497
  132. Yusuf S, Zhao F, Mehta SR, et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med. 2001;345:494–502
  133. Cannon CP, Battler A, Brindis RG, et al.  ACC key elements and data definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: a report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001;38:2114–2130
  134. Kuntz RE, Baim DS. Defining restenosis: newer clinical and angiographic paradigms. Circulation. 1993;83:1310–1323
  135. Serruys PW, Kay IP, Disco C, et al.  Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the Belgian Netherlands Stent study (BENESTENT) I, BENESTENT II pilot, BENESTENT II and Multicenter Ultrasound Stent in Coronaries (MUSIC) trials. J Am Coll Cardiol. 1999;34:1067–1074
  136. Apple FS, Wu AHB. Myocardial infarction redefined: role of cardiac troponin testing. Clin Chem. 2001;47:377–379

☆ Supported by unrestricted educational grants from: Aventis Pharmaceuticals, Abbott Diagnostic, COR Therapeutics, Inc., First Medical, The Medicines Company, Merck & Co., Pfizer Inc., Proctor & Gamble Pharmaceuticals, Roche Diagnostics Corporation, Schering-Plough Research Institute, Wyeth-Ayerst Research

☆☆ Reprint requests: L. Kristin Newby, MD, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715-7969.

★ E-mail: newby001@mc.duke.edu

★★ *A complete list of participants is listed in the Appendix.

PII: S0002-8703(02)00220-X

doi: 10.1067/mhj.2002.129778

American Heart Journal
Volume 144, Issue 6 , Pages 957-980 , December 2002

Article Tools

* Image Usage & Resolution